Please check your internet connection and try again.
# Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at
## Overview
Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is a combination medication containing aspirin and dipyridamole. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) with antiplatelet effects. Dipyridamole is a phosphodiesterase inhibitor that also inhibits adenosine uptake, leading to vasodilation and antiplatelet effects.
## Primary Indications
* Prevention of thromboembolism in patients who have a mechanical heart valve.
## Adult Dosing
* **Oral:** Typically 25 mg dipyridamole and 81 mg aspirin (extended-release) twice daily.
* Some sources suggest 25 mg dipyridamole and 75 mg aspirin (immediate-release) four times daily. Always refer to specific product labeling or local protocol.
## Pediatric Dosing
Pediatric dosing is not established.
## Dose Adjustments
* **Renal Impairment:** Use with caution. No specific dose adjustments are universally recommended; monitor closely.
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are universally recommended; monitor closely.
## Contraindications
* Known hypersensitivity to aspirin, dipyridamole, or any component of the formulation.
* Bleeding disorders.
* Active peptic ulcer disease.
* Patients who are severely asthmatic, have bronchospasm, or other hypersensitivity to NSAIDs.
* Inhibitors of adenosine deaminas, xanthine oxidase, or phosphodiesterase.
## Adverse Effects
* **Common:** Headache, dizziness, nausea, diarrhea, abdominal pain, rash.
* **Serious:** Bleeding (including gastrointestinal, intracranial), bronchospasm, angioedema.
## Key Drug Interactions
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
* **Adenosine:** Potentiates the effects of adenosine, leading to profound bradycardia, hypotension, and potentially cardiac arrest. Coadministration is generally contraindicated.
* **Anticholinergics:** Dipyridamole may reduce the efficacy of anticholinergic agents.
* **NSAIDs:** Increased risk of gastrointestinal bleeding.
* **Warfarin:** Increased risk of bleeding.
## Monitoring
* Signs and symptoms of bleeding.
* Renal and hepatic function, particularly in patients with pre-existing impairment.
## Clinical Pearls
* The extended-release formulation of dipyridamole should not be crushed or chewed.
* Due to the risk of severe bradycardia and hypotension with adenosine administration, concomitant use should be avoided.
* Patients with mechanical heart valves have a high risk of thromboembolic events; adherence to therapy is critical.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete details before making any treatment decisions.*
